Decoy Therapeutics (FRA:FP11) Total Tax Payable: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FP11 Decoy Therapeutics Inc FRA:FP11
23 GF Score
Price €5.23
! 3 Warning Signs
View Full Analysis

What is Decoy Therapeutics Total Tax Payable?

Decoy Therapeutics FRA:FP11 23 Total Tax Payable is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:FP11 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Decoy Therapeutics's Total Tax Payable for the quarter that ended in Jun. 2026 was €0.00 Mil.

Decoy Therapeutics Total Tax Payable Related Terms

Decoy Therapeutics Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Decoy Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Decoy Therapeutics Total Tax Payable Chart

Decoy Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Decoy Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:FP11
23GF Score
Decoy Therapeutics Inc FRA:FP11
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Decoy Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of €0.00 Mil mean?
Decoy Therapeutics (FRA:FP11) has a Total Tax Payable of €0.00 Mil as of Jun. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Decoy Therapeutics and its competitors.
Is Decoy Therapeutics' Total Tax Payable too high?
Decoy Therapeutics' current Total Tax Payable is €0.00 Mil. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' Total Tax Payable compare to PKTX and CASIF?
Decoy Therapeutics' Total Tax Payable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Decoy Therapeutics and its competitors. Decoy Therapeutics's current Total Tax Payable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (FRA:FP11) has a current Total Tax Payable of €0.00 Mil. The current Total Tax Payable is €0.00 Mil. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Decoy Therapeutics (FRA:FP11), the current Total Tax Payable is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Decoy Therapeutics Business Description

Other Exchanges DCOY:USA
Address 2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score

Get the complete analysis for FRA:FP11

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.23
Price